Live News NEWS FLASH L impact Sep 29, 2026, 06:38 AM UTC AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027 AB Science SA EURONEXT:AB AB SquawkNews Newsroom